Retinoblastoma in Hong Kong from 2008 to 2019: looking back and moving forward


  • Emily Suhan Wong Hong Kong Eye Hospital The Chinese University of Hong Kong
  • Alison Yin Yung Chan Hong Kong Eye Hospital The Chinese University of Hong Kong
  • Carol Po Sang Lam Hong Kong Eye Hospital The Chinese University of Hong Kong
  • Winnie Wai Ying Lau The Hong Kong Ophthalmic Associates
  • Jason Cheuk Sing Yam Hong Kong Eye Hospital The Chinese University of Hong Kong
  • Christopher Bing On Yu Premiere Medical Centre


Eye enucleation, Hong Kong, Incidence, Retinoblastoma, Treatment outcome


Purpose: To report the incidence, clinical features, and treatment outcomes of retinoblastoma at a tertiary referral center in Hong Kong.

Methods: Medical records of all patients with retinoblastoma presenting to Hong Kong Eye Hospital from 2008 to 2019 were reviewed.

Results: 75 eyes in 55 patients were treated for retinoblastoma during the 10-year study period. The mean age at presentation was 19.8±16.4 months. The mean duration of symptoms before diagnosis was 1.1±2.1 months. The most common presenting sign was leukocoria and/or strabismus (n=33, 60.1%). 65% of patients presented with advanced disease of groups D and E. The tumor was unilateral (n=35, 63.6%), bilateral (n=18, 32.7%), or trilateral (n=2, 3.6%). The enucleation rate was 0% in groups A to C, 70% in group D, and 93.3% in group E. With the introduction of intra-arterial chemotherapy since 2016, the globe salvage rate has increased from 29.4% to 33.3% in group D eyes and from 4.5% to 12.5% in group E eyes. The overall globe salvage rate was 40.0%, and the overall 5-year survival rate was 100%.

Conclusions: The prognosis of retinoblastoma is good in cases with early detection and appropriate treatment. Unfortunately, most patients presented with relatively advanced disease, which lowers the overall globe salvage rate. There is a need for enhanced public awareness and education for healthcare professionals to facilitate early detection and improve ocular outcomes for children with retinoblastoma.


Keller AZ. Histology, survivorship and related factors in the epidemiology of eye cancers. Am J Epidemiol 1973;97:386-93.

Rao R, Honavar SG. Retinoblastoma. Indian J Pediatr 2017;84:937-44.

Jain M, Rojanaporn D, Chawla B, Sundar G, Gopal L, Khetan V. Retinoblastoma in Asia. Eye (Lond) 2019;33:87-96.

Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma. Lancet 2012;379:1436-46.

Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, Brisse H, Doz F. Retinoblastoma update [in French]. Arch Pediatr 2016;23:112-6.

Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol 2010;21:203-12.

Yam JCS, Ko STC, Chan CWN. A 10-year retrospective study of retinoblastoma in 2 regional hospitals in Hong Kong. Hong Kong J Ophthalmol 2008;12:7-10.

Razek AA, Elkhamary S. MRI of retinoblastoma. Br J Radiol 2011;84:775-84.

Shields CL, Fulco EM, Arias JD, et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye (Lond) 2013;27:253-64.

Hong Kong Government Census and Statistics Department. Fertility Trend in Hong. Kong. Hong Kong: Hong Kong Government; 2019.

Eagle RC Jr. High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study. Arch Pathol Lab Med 2009;133:1203-9.

Kaliki S, Shields CL, Rojanaporn D, et al. High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology 2013;120:997-1003.

Chung SE, Sa HS, Koo HH, Yoo KH, Sung KW, Ham DI. Clinical manifestations and treatment of retinoblastoma in Korea. Br J Ophthalmol 2008;92:1180-4.

Chen YH, Lin HY, Hsu WM, Lee SM, Cheng CY. Retinoblastoma in Taiwan: incidence and survival characteristics from 1979 to 2003. Eye (Lond) 2010;24:318-22.

Aung L, Chan YH, Yeoh EJ, Tan PL, Quah TC. Retinoblastoma: a recent experience at the National University Hospital, Singapore. Ann Acad Med Singapore 2009;38:693-8.

Mahoney MC, Burnett WS, Majerovics A, Tanenbaum H. The epidemiology of ophthalmic malignancies in New York State. Ophthalmology 1990;97:1143-7.

Mallipatna AC, Sutherland JE, Gallie BL, Chan H, Héon E. Management and outcome of unilateral retinoblastoma. J AAPOS 2009;13:546-50.

Stafford WR, Yanoff M, Parnell BL. Retinoblastomas initially misdiagnosed as primary ocular inflammations. Arch Ophthalmol 1969;82:771-3.

Binder PS. Unusual manifestations of retinoblastoma. Am J Ophthalmol 1974;77:674-9.

Chawla B, Khurana S, Sen S, Sharma S. Clinical misdiagnosis of retinoblastoma in Indian children. Br J Ophthalmol 2014;98:488-93.

Chang Y, Shi J, Zhao J, et al. Retinoblastoma in Chinese children aged five to fourteen years. Ophthalmologica 2015;233:222-9.

Sanders BM, Draper GJ, Kingston JE. Retinoblastoma in Great Britain 1969-80: incidence, treatment, and survival. Br J Ophthalmol 1988;72:576-83.

Moll AC, Kuik DJ, Bouter LM, et al. Incidence and survival of retinoblastoma in The Netherlands: a register based study 1862-1995. Br J Ophthalmol 1997;81:559-62.

Broaddus E, Topham A, Singh AD. Survival with retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 2009;93:24-7.

Chantada GL, Qaddoumi I, Canturk S, et al. Strategies to manage retinoblastoma in developing countries. Pediatr Blood Cancer 2011;56:341-8.

Su WW, Kao LY. Retinoblastoma in Taiwan: the effect of a government-sponsored national health insurance program on the treatment and survival of patients with retinoblastoma. J Pediatr Ophthalmol Strabismus 2006;43:358-62.

The Committee for the National Registry of Retinoblastoma. Survival rate and risk factors for patients with retinoblastoma in Japan. Jpn J Ophthalmol 1992;36:121-31.

Lim FP, Soh SY, Iyer JV, Tan AM, Swati H, Quah BL. Clinical profile, management, and outcome of retinoblastoma in Singapore, J Pediatr Ophthalmol Strabismus 2013;50:106-

Chung SE, Sa HS, Koo HH, Yoo KH, Sung KW, Ham DI. Clinical manifestations and treatment of retinoblastoma in Korea. Br J Ophthalmol 2008;92:1180-4.

Kivelä T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 1999;17:1829-37.

de Jong MC, Kors WA, de Graaf P, Castelijns JA, Kivelä T, Moll AC. Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol 2014;15:1157-67.

Dunkel IJ, Chan HS, Jubran R, et al. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer 2010;55:149-52.

Suzuki S, Aihara Y, Fujiwara M, Sano S, Kaneko A. Intravitreal injection of melphalan for intraocular retinoblastoma. Jpn J Ophthalmol 2015;59:164-72.

Shields CL, De Potter P, Himelstein BP, Shields JA, Meadows AT, Maris JM. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1330-

Greenwald MJ, Strauss LC. Treatment of intraocular retinoblastoma with carboplatin and etoposide chemotherapy. Ophthalmology 1996;103:1989-97.

Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000;18:12-7.

Beck MN, Balmer A, Dessing C, Pica A, Munier F. First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular

retinoblastoma. J Clin Oncol 2000;18:2881-7.

Abramson DH, Shields CL, Jabbour P, et al. Metastatic deaths in retinoblastoma patients treated with intraarterial chemotherapy (ophthalmic artery chemosurgery) worldwide. Int J Retina Vitreous 2017;3:40.

Fernandes AG, Pollock BD, Rabito FA. Retinoblastoma in the United States: a 40-year incidence and survival analysis. J Pediatr Ophthalmol Strabismus 2018;55:182-8.

Gregersen PA, Urbak SF, Funding M, Overgaard J, Jensen UB, Alsner J. Danish retinoblastoma patients 1943-2013: genetic testing and clinical implications. Acta Oncol 2016;55:412–7.




How to Cite

Wong ES, Chan AYY, Lam CPS, Lau WWY, Yam JCS, Yu CBO. Retinoblastoma in Hong Kong from 2008 to 2019: looking back and moving forward. Hong Kong J Ophthalmol [Internet]. 2020Jun.23 [cited 2024Jun.15];24(1):6-10. Available from:



Original Articles